ES2104733T3 - Derivados de indol. - Google Patents

Derivados de indol.

Info

Publication number
ES2104733T3
ES2104733T3 ES91920239T ES91920239T ES2104733T3 ES 2104733 T3 ES2104733 T3 ES 2104733T3 ES 91920239 T ES91920239 T ES 91920239T ES 91920239 T ES91920239 T ES 91920239T ES 2104733 T3 ES2104733 T3 ES 2104733T3
Authority
ES
Spain
Prior art keywords
aryl
alkyl
hydrogen
nr5r6
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91920239T
Other languages
English (en)
Inventor
John Eugene Macor
Martin James Wythes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24393510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2104733(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2104733T3 publication Critical patent/ES2104733T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
  • Lasers (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPUESTOS DE FORMULA (I), EN DONDE N ES 0, 1 O 2; R1 ES HIDROGENO; R2 SE SELECCIONA DE HIDROGENO, HALOGENO, CIANO, OR4, -(CH2)M (C=O)NR5R6, -(CH2)M -(CH2)M NR7SO2R8, -(CH2)M -(CH2)M NR7(C=O)OR9, Y -CH=CH(CH2)YR10; R3 SE SELECCIONA DE HIDROGENO Y ALQUILO C1 A C6 LINEAL O RAMIFICADO; R4 SE SELECCIONA DE HIDROGENO, ALQUILO C1 A C6, O ARILO; R5 Y R6 SE SELECCIONAN INDEPENDIENTEMENTE DE HIDROGENO, ALQUILO C1 A C6, ARILO, O ALQUILO ANILLO DE 4, 5 O 6 MIEMBROS; R7 Y R8 SE SELECCIONAN INDEPENDIENTEMENTE DE HIDROGENO, ALQUILO C1 A C6, ARILO, Y ALQUILO LO C1 A C3; R9 SE SELECCIONA DE HIDROGENO, ALQUILO C1 A C6, ARILO, O ALQUILO R6 Y -SO2NR5R6, EN DONDE R5 Y R6 SE DEFINEN COMO ANTERIORMENTE, Y -NR7(C=O)R8, -NR7SO2R8, -NR7(C=O)NR5R6, -S(O)XR8 Y -NR7(C=O)OR9, EN DONDE R7, R8, Y R9 SON COMO SE DEFINIERON ANTERIORMENTE; Y ES 0, 1 O 2; X ES 1 O 2; M ES 0, 1, 2, O 3; Y LOS GRUPOS ARILO ANTERIORES Y LAS MITADES ARILO DE LOS ANTERIORES GRUPOS ALQUILO - ARILO SE SELECCIONAN INDEPENDIENTEMENTE ENTRE FENILO O FENILO SUSTITUIDO, EN DONDE DICHO FENILO SUSTITUIDO PUEDE ESTAR SUSTITUIDO CON UNO O TRES GRUPOS ESCOGIDOS DE ALQUILO C1 A C4, HALOGENO, HIDROXILO, CIANO, CARBOXIAMIDO, NITRO, Y ALCOXILO C1 A C4 Y LAS SALES DE ELLOS FARMACEUTICAMENTE ACEPTABLES SON NUEVOS. ESTOS COMPUESTOS SE USAN COMO PSICOTERAPEUTICOS Y SON POTENTES AGONISTAS DE SEROTONINA (5-HT1) Y SE PUEDEN USAR EN EL TRATAMIENTO DE DEPRESION, ANSIEDAD, DESORDENES ALIMENTICIOS, OBESIDAD, ABUSO DE DROGAS, CEFALEA EN RACIMOS, MIGRAÑA, DOLOR, HEMICRANIA PAROXISMICA CRONICA Y CEFALEA ASOCIADA CON DESORDENES VASCULARES, Y OTROS DESORDENES QUE SURGEN A PARTIR DE DEFICIENTE NEUROTRANSMISION SEROTONERGICA. LOS COMPUESTOS PUEDEN TAMBIEN SER USADOS COMO ANTIHIPERTENSIVOS QUE ACTUAN CENTRALMENTE Y VASODILATADORES.
ES91920239T 1990-10-15 1991-10-08 Derivados de indol. Expired - Lifetime ES2104733T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59792890A 1990-10-15 1990-10-15

Publications (1)

Publication Number Publication Date
ES2104733T3 true ES2104733T3 (es) 1997-10-16

Family

ID=24393510

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91920239T Expired - Lifetime ES2104733T3 (es) 1990-10-15 1991-10-08 Derivados de indol.

Country Status (33)

Country Link
EP (1) EP0592438B1 (es)
JP (2) JP2575272B2 (es)
KR (1) KR0179053B1 (es)
CN (1) CN1039322C (es)
AT (1) ATE157361T1 (es)
AU (1) AU651637B2 (es)
BG (1) BG61975B1 (es)
BR (2) BR9106978A (es)
CA (1) CA2091562C (es)
DE (3) DE69127468T2 (es)
DK (1) DK0592438T5 (es)
EG (1) EG20224A (es)
ES (1) ES2104733T3 (es)
FI (1) FI105812B (es)
GR (1) GR3025087T3 (es)
HU (2) HUT64326A (es)
IE (1) IE913555A1 (es)
IL (3) IL99701A (es)
LU (1) LU90902I2 (es)
MX (1) MX9101606A (es)
MY (1) MY111683A (es)
NL (1) NL300070I2 (es)
NO (3) NO305121B1 (es)
NZ (2) NZ240217A (es)
OA (1) OA09874A (es)
PL (3) PL170330B1 (es)
PT (1) PT99218B (es)
RO (1) RO111767B1 (es)
RU (1) RU2095360C1 (es)
SG (1) SG54270A1 (es)
WO (1) WO1992006973A1 (es)
YU (1) YU48088B (es)
ZA (1) ZA918156B (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
UA41297C2 (uk) * 1991-11-25 2001-09-17 Пфайзер, Інк. Похідні індолу, фармацевтична композиція і спосіб лікування
TW288010B (es) * 1992-03-05 1996-10-11 Pfizer
PL172405B1 (en) * 1992-04-07 1997-09-30 Pfizer Derivatives of indole
DE69307875T2 (de) * 1992-04-10 1997-05-22 Pfizer Acylaminoindolderivate als 5-ht1 agonisten
GB9207930D0 (en) * 1992-04-10 1992-05-27 Pfizer Ltd Indoles
GB9208161D0 (en) * 1992-04-14 1992-05-27 Pfizer Ltd Indoles
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
TW251284B (es) * 1992-11-02 1995-07-11 Pfizer
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
IT1271352B (it) * 1993-04-08 1997-05-27 Boehringer Ingelheim Italia Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
CA2157397C (en) * 1993-04-22 1999-07-06 Martin James Wythes Indole derivatives as 5-ht1-like agonists for use in migraine
AP486A (en) * 1993-04-27 1996-04-16 Pfizer Indole derivatives.
ES2070772B1 (es) * 1993-08-09 1996-02-16 Pfizer Derivados de acilaminoindol
KR100191973B1 (ko) * 1993-08-31 1999-06-15 디. 제이. 우드, 스피겔 알렌 제이 5-아릴인돌 유도체
EP0775131A2 (de) * 1994-08-03 1997-05-28 ASTA Medica Aktiengesellschaft Indol-, indazol-, pyridopyrrol- und pyridopyrazol-derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender wirkung
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
WO1996011923A1 (en) * 1994-10-12 1996-04-25 Pfizer Limited Indole derivative for the treatment of migraine
GB9420529D0 (en) * 1994-10-12 1994-11-30 Pfizer Ltd Indoles
AU726560B2 (en) * 1994-10-12 2000-11-09 Pfizer Research And Development Company, N.V./S.A. Use of indole derivatives for the treatment of various diseases
GB9424471D0 (en) * 1994-12-03 1995-01-18 Pfizer Ltd Treatment of emesis
MX9706969A (es) * 1995-03-20 1997-11-29 Lilly Co Eli 3-(1,2,3,6-tetrahidropiridin-4-il)-1h-indoles y 3-(piperidin-4-il)-1h-indoles sustituidos en la posicion 5: agonistas del 5-ht1f novedosos.
GB9510223D0 (en) * 1995-05-20 1995-07-19 Pfizer Ltd Therapeutic agent
US5945118A (en) * 1995-09-29 1999-08-31 Pfizer Inc Indole derivative for the treatment of migraine
GB9714383D0 (en) * 1997-07-08 1997-09-10 Pfizer Ltd Improved process
AU3170099A (en) * 1998-04-16 1999-11-08 Yamanouchi Pharmaceutical Co., Ltd. Remedies for obesity
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
JP2000336074A (ja) 1999-03-24 2000-12-05 Sumitomo Chem Co Ltd ［２−（アリールスルホニル）エテニル］ベンゼン誘導体の製造方法
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
US6515141B1 (en) * 1999-08-26 2003-02-04 Fujisawa Pharmaceutical Co., Ltd. Process for the preparation of indole derivatives or salts thereof
GB9923314D0 (en) * 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
FR2799463B1 (fr) * 1999-10-12 2004-04-16 Adir Nouveaux composes cyano-indoles inhibiteurs de recapture de serotonine, leur procede de preparation et ces compositions pharmaceutiques qui les contiennent
US20030166704A1 (en) 2000-12-20 2003-09-04 Pfizer Inc. New process
GB0031094D0 (en) * 2000-12-20 2001-01-31 Pfizer Ltd New Process
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
EP3168218B1 (en) 2001-08-15 2018-11-14 Pharmacia & Upjohn Company LLC A crystal comprising an l-malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide for use as a medicament
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
EP1644004A4 (en) 2003-06-20 2010-10-06 Ronald Aung-Din LOCAL THERAPY FOR THE TREATMENT OF MIGRAINS, MUSCLE CLARIFICATIONS, MUSCLE SPASMS, SPASTICITY AND RELATED CONDITIONS
KR20080016648A (ko) 2005-06-15 2008-02-21 화이자 리미티드 기생충 방제용 치환된 아릴피라졸
US7645786B2 (en) 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
WO2006079999A2 (en) * 2006-04-09 2006-08-03 Barth Frederik H Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist
US20090299077A1 (en) * 2008-05-22 2009-12-03 Vinod Kumar Kansal Salts of (R)-5-(2phenylsulphonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole, 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole and of eletriptan
WO2010005507A1 (en) 2008-06-30 2010-01-14 Afgin Pharma, Llc Topical regional neuro-affective therapy
EP2149573A1 (en) * 2008-08-01 2010-02-03 Laboratorios Del. Dr. Esteve, S.A. Substituted indole sulfonamide compounds their preparation and use as medicaments
IT1393700B1 (it) 2009-04-22 2012-05-08 F S I Fabbrica Italiana Sint Sintesi di 3-{[(2r)-1-metilpirrolidin-2-il]metil}-5-[2-(fenilsulfonil)etil]-1h-indolo
WO2011004391A2 (en) 2009-06-25 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of eletriptan and its salt thereof
WO2011024039A1 (en) * 2009-08-25 2011-03-03 Ramesh Babu Potluri Synthesis of novel 5-(2-(phenylsulfonyl)ethyl)-1h-indole derivatives
WO2011089614A1 (en) * 2010-01-19 2011-07-28 Sms Pharmaceuticals Limited PROCESS FOR PREPARING ELETRIPTAN HYDROBROMIDE HAVING α-FORM
CN102606426B (zh) * 2012-03-02 2014-05-21 王仲彦 踏步健身发电装置
WO2014063752A1 (en) 2012-10-26 2014-05-01 Synthon Bv Process for making crystalline form alpha of eletriptan hydrobromide
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CN103408535B (zh) * 2013-08-13 2016-03-02 张家港威胜生物医药有限公司 一种依来曲普坦中间体-5-溴-3-(n-甲基吡咯啉-2-基甲基)-1h-吲哚合成工艺
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
BR112017018944A2 (pt) 2015-03-02 2018-05-15 Afgin Pharma Llc método de tratamento de um estado ou condição de doença em humanos com um medicamento carbinóide, e, método de tratamento de um estado ou condição de doença em um mamífero diferente de um humano com medicamento(s) carbinóide(s)
JP2019502761A (ja) 2016-01-21 2019-01-31 ラボラトリオス レヴィ エセエレ （（ｒ）−３−［（−１−メチルピロリジン−２−イル）メチル］−５−（２−フェニルスルホニルエチル）−１ｈ−インドールを作製する方法
CN106065008B (zh) * 2016-06-16 2018-06-05 黑龙江中医药大学 一种具有改善睡眠作用的吲哚-2-酰胺类化合物及其应用
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
TR201616365A1 (tr) 2016-11-14 2018-05-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deksketoprofen ve eletri̇ptanin oral farmasöti̇k kompozi̇syonlari
TR201619983A2 (tr) 2016-12-29 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Di̇klofenak ve eletri̇ptanin farmasöti̇k formülasyonlari
KR102129947B1 (ko) 2018-06-08 2020-07-03 김종창 콘크리트 타설을 위한 입체형 와이어 메쉬
EP3766483A1 (en) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan
WO2021148868A1 (en) 2020-01-22 2021-07-29 Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. Eletriptan hydrobromide for treatment of spinal cord injury and improvement of locomotor function
WO2023150547A2 (en) * 2022-02-01 2023-08-10 Caamtech, Inc. Psychedelic compounds and their therapeutic uses

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL74527C (es) *
US2773875A (en) * 1952-03-28 1956-12-11 Hoffmann La Roche Indole derivatives and method for producing same
GB886684A (en) * 1957-09-17 1962-01-10 Upjohn Co Improvements in or relating to heterocyclic compounds and the manufacture thereof
GB851780A (en) * 1958-02-25 1960-10-19 Rhone Poulenc Sa New indole derivatives
US3037031A (en) * 1959-08-04 1962-05-29 Warner Lambert Pharmaceutical Derivatives of 3-(2-aminoalkyl)-5-indolol and process therefor
GB893707A (en) * 1960-03-01 1962-04-11 Roche Products Ltd Novel tryptamine derivatives and a process for the manufacture thereof
GB966562A (en) * 1961-04-06 1964-08-12 Parke Davis & Co Amine compounds and means of producing the same
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
NO305121B1 (no) 1999-04-06
JP2575272B2 (ja) 1997-01-22
LU90902I2 (fr) 2002-06-26
EG20224A (en) 1997-12-31
HU225055B1 (en) 2006-05-29
NO2001019I1 (no) 2001-12-03
DE69127468T2 (de) 1998-01-02
DE69127468D1 (de) 1997-10-02
CN1039322C (zh) 1998-07-29
AU8950491A (en) 1992-05-20
DK0592438T3 (da) 1997-09-29
BG97632A (bg) 1994-03-31
AU651637B2 (en) 1994-07-28
NO931378L (no) 1993-04-14
CN1062529A (zh) 1992-07-08
BR9106978A (pt) 1993-09-28
OA09874A (en) 1994-09-15
ATE157361T1 (de) 1997-09-15
BG61975B1 (bg) 1998-11-30
FI931667A (fi) 1993-04-14
DE9190141U1 (es) 1993-07-15
PT99218A (pt) 1992-09-30
ZA918156B (en) 1993-04-14
IL115117A0 (en) 1995-12-08
JPH093063A (ja) 1997-01-07
IL99701A (en) 1996-10-31
HU9301098D0 (en) 1993-07-28
MX9101606A (es) 1992-06-05
FI105812B (fi) 2000-10-13
RO111767B1 (ro) 1997-01-30
NZ240217A (en) 1995-05-26
JP2677777B2 (ja) 1997-11-17
RU2095360C1 (ru) 1997-11-10
PL168919B1 (pl) 1996-05-31
FI931667A0 (fi) 1993-04-14
GR3025087T3 (en) 1998-01-30
PL170330B1 (pl) 1996-11-29
SG54270A1 (en) 1998-11-16
IL99701A0 (en) 1992-08-18
DK0592438T5 (da) 1999-12-06
NZ270675A (en) 1997-07-27
NL300070I2 (nl) 2002-03-01
MY111683A (en) 2000-11-30
YU165391A (sh) 1994-01-20
IL115117A (en) 1996-11-14
PT99218B (pt) 1999-04-30
NO931378D0 (no) 1993-04-14
BR1100080A (pt) 2000-06-06
NO985607D0 (no) 1998-12-01
JPH05507288A (ja) 1993-10-21
NO985607L (no) 1998-12-01
IE913555A1 (en) 1992-04-22
CA2091562A1 (en) 1992-04-16
DE10299004I1 (de) 2002-05-08
PL169987B1 (en) 1996-09-30
EP0592438A1 (en) 1994-04-20
DE10299004I2 (de) 2006-03-16
HUT64326A (en) 1993-12-28
NL300070I1 (nl) 2002-02-01
EP0592438B1 (en) 1997-08-27
KR0179053B1 (ko) 1999-03-20
YU48088B (sh) 1997-01-08
CA2091562C (en) 2001-03-27
WO1992006973A1 (en) 1992-04-30

Similar Documents

Publication Publication Date Title
ES2104733T3 (es) Derivados de indol.
NO960818D0 (no) 5-Arylindol-derivater
MY108909A (en) Indole derivatives

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 592438

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: ELETRIPTAN (RELPAX, RELERT)

Spc suppl protection certif: C200100041

Filing date: 20011113

SPCG Supplementary protection certificate granted

Free format text: ELETRIPTAN (RELPAX, RELERT).

Spc suppl protection certif: C200100041

Filing date: 20011113

Expiry date: 20160212

Effective date: 20040614